Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Trial watch

Insulin initiation for type 2 diabetes mellitus in primary care

Nature Reviews Endocrinology volume 13, pages 317–318 (2017)Cite this article

Subjects

Enhanced insulin initiation in primary care is associated with improvements in glycaemic control without deterioration in emotional well-being, according to recent results from an Australian randomized controlled trial of a novel model of care that incorporates theory-based change and an enhanced role for nurse practitioners.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. International Diabetes Federation. IDF Diabetes Atlas 7th edn (IDF, 2015).

  2. Furler, J. et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ 356, j783 (2017).

    Article  Google Scholar 

  3. Bodenheimer, T., Wagner, E. H. & Grumbach, K. Improving primary care for patients with chronic illness. JAMA 288, 1775–1779 (2002).

    Article  Google Scholar 

  4. Paul, S. K., Klein, K., Thorsted, B. L., Wolden, M. L. & Khunti, K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc. Diabetol. 14, 100 (2015).

    Article  Google Scholar 

  5. Inzucchi, S. E. et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149 (2015).

    Article  Google Scholar 

  6. Rosenstock, J. et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care 39, 2026–2035 (2016).

    Article  CAS  Google Scholar 

  7. Davies, M. J., Glah, D., Chubb, B., Konidaris, G. & McEwan, P. Cost effectiveness of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting. Pharmacoeconomics 34, 953–966 (2016).

    Article  Google Scholar 

  8. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care 38, 1583–1591 (2015).

  9. Wang, G. et al. Telemedicine in the management of type 2 diabetes. Am. J. Med. Sci. 353, 1–5 (2017).

    Article  Google Scholar 

  10. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530 (2016).

Download references

Acknowledgements

The authors acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care — East Midlands (NIHR CLAHRC — EM), the Leicester Clinical Trials Unit and the NIHR Leicester–Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester.

Author information

Authors and Affiliations

  1. Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4PW, UK

    Melanie J. Davies & Sudesna Chatterjee

Authors
  1. Melanie J. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sudesna Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie J. Davies.

Ethics declarations

Competing interests

M.J.D. has acted as consultant, advisory board member and speaker for AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis; as an advisory board member for Servier; and as a speaker for Mitsubishi Tanabe Pharma Corporation and Takeda Pharmaceuticals International. She has received grants in support of investigator and investigator-initiated trials from Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk and Sanofi-Aventis and speaker fees, educational funding or both from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen and Novo Nordisk. S.C. has received speaker fees, educational funding or both from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen and Novo Nordisk; and grants in support of investigator-initiated trials from Boehringer Ingelheim and Janssen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davies, M., Chatterjee, S. Insulin initiation for type 2 diabetes mellitus in primary care. Nat Rev Endocrinol 13, 317–318 (2017). https://doi.org/10.1038/nrendo.2017.41

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2017.41

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing